Stock Screener App

무료 -

설치하다

0.00

100.00% -53.01

after-market

시간 외 거래: 53.02 53.02 +

Soleno Therapeutics Inc (SLNO)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할

Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스

Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits

Soleno (SLNO) Earnings Reading: The EPS Result Is Below Expectation in the Latest Reading ; Share Performance Is Not Yet AvailableEarnings Seasonality - Vinanet

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect - ACCESS Newswire

SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Wellington reports 0.0% stake in Soleno Therapeutics (SLNO) in amended 13G - Stock Titan

Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap - The National Law Review

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact - Stock Titan

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results - TradingView

Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Neurocrine executive who led $2.9B Soleno deal gets new role - Stock Titan

Trading Systems Reacting to (SLNO) Volatility - Stock Traders Daily

2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect | Press Release - Stockhouse

2026-07-14 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect | Press Release - Stockhouse

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating A Stable Path In Biotechnology - DirectorsTalk Interviews

Price to earnings forward of Soleno Therapeutics Inc – LS:A3DS0P - TradingView

Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review

2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation | Press Release - Stockhouse

Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo

Soleno Therapeutics (SLNO) Cantor Global Healthcare Conference 2025 Summary - Quartr

Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Soleno Therapeutics (SLNO) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr

Soleno Therapeutics (SLNO) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr

Soleno Therapeutics (SLNO) Q4 2025 earnings summary - Quartr

Soleno Therapeutics (SLNO) Jefferies London Healthcare Conference 2024 Summary - Quartr

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Steady Performance with Limited Upside in the Biotech Sector - DirectorsTalk Interviews

Soleno Therapeutics Inc. Investors with Substantial Losses Have O - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Stable Horizon with Strong Cash Reserves - DirectorsTalk Interviews

How Soleno Therapeutics Inc. (SLNO) Affects Rotational Strategy Timing - Stock Traders Daily

Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirt - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect - ACCESS Newswire

2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect | Press Release - Stockhouse

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating the Biotech Sector with a Strong Free Cash Flow - DirectorsTalk Interviews

Soleno Therapeutics Inc (SLNO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Soleno Therapeutics Inc (SLNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

2026-06-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect | Press Release - Stockhouse

Soleno Therapeutics Inc (SLNO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Reach Out - ACCESS Newswire

Soleno Therapeutics presents new Vykat XR data at ENDO - The Pharma Letter

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Evaluating The Biotech's Steady Trajectory - DirectorsTalk Interviews

RPRX

$61.31

1.21%

INSM

$125.77

0.55%

BNTX

$116.57

5.12%

ALNY

$236.22

3.02%

ONC

$374.47

1.44%

RVMD

$209.46

1.07%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개